Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$5.97 -4.3%	$5.34	$3.56 ▼ $12.92	$336.91M	0.41	353,796 shs	198,157 shs
BNTC Benitec Biopharma	$11.04 -6.0%	$14.01	$7.05 ▼ $17.15	$289.80M	0.37	58,648 shs	98,440 shs
CLLS Cellectis	$1.82 -5.7%	$1.53	$1.10 ▼ $2.43	$101.16M	2.91	150,982 shs	133,053 shs
HUMA Humacyte	$2.33 -3.7%	$2.35	$1.15 ▼ $9.79	$361.43M	1.89	3.78 million shs	1.55 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	-6.28%	+1.36%	+47.77%	-47.31%
BNTC Benitec Biopharma	0.00%	-13.62%	-26.10%	-19.71%	+13.81%
CLLS Cellectis	0.00%	+14.47%	+31.88%	+25.52%	-13.74%
HUMA Humacyte	0.00%	+0.87%	-1.27%	+38.69%	-71.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	1.6181 of 5 stars	3.6	1.0	0.0	1.7	0.0
BNTC Benitec Biopharma	1.8977 of 5 stars	3.6	1.0	3.4	0.8	0.0
CLLS Cellectis	2.7767 of 5 stars	3.5	4.0	0.6	2.5	0.6
HUMA Humacyte	1.5241 of 5 stars	3.5	1.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.25	Buy	$30.00	402.51% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	115.88% Upside
CLLS Cellectis	3.00	Buy	$4.00	119.78% Upside
HUMA Humacyte	3.00	Buy	$11.71	402.76% Upside

Current Analyst Ratings Breakdown

Latest CLLS, BNTC, HUMA, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/13/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
BNTC Benitec Biopharma	$80K	3,622.50	N/A	N/A	$4.68 per share	2.36
CLLS Cellectis	$49.22M	2.06	N/A	N/A	$2.36 per share	0.77
HUMA Humacyte	$517K	699.09	N/A	N/A	($0.41) per share	-5.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	8/11/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)

Latest CLLS, BNTC, HUMA, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	HUMA Humacyte	-$0.15	N/A	N/A	N/A	$0.94 million	N/A
8/11/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	N/A	N/A	N/A	N/A	N/A
8/5/2025	N/A	CLLS Cellectis	-$0.15	N/A	N/A	N/A	$10.07 million	N/A
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	17.39	17.39
BNTC Benitec Biopharma	0.01	14.80	14.80
CLLS Cellectis	0.44	1.67	1.67
HUMA Humacyte	0.36	3.68	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
BNTC Benitec Biopharma	52.19%
CLLS Cellectis	63.90%
HUMA Humacyte	44.71%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
BNTC Benitec Biopharma	1.30%
CLLS Cellectis	16.41%
HUMA Humacyte	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable

CLLS, BNTC, HUMA, and ATXS Headlines

Recent News About These Companies

Humacyte (NASDAQ:HUMA) Rating Lowered to Sell at Wall Street Zen

July 19 at 2:25 AM | marketbeat.com

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

July 18 at 10:07 PM | msn.com

Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

July 15, 2025 | msn.com

Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

July 15, 2025 | zacks.com

Humacyte Shares Climb on Symvess ECAT Listing - Morningstar

July 10, 2025 | morningstar.comM

Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $11.71

July 10, 2025 | americanbankingnews.com

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

July 9, 2025 | zacks.com

D. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

July 9, 2025 | marketbeat.com

Humacyte jumps as DoD issues ECAT listing approval for Symvess

July 9, 2025 | msn.com

Humacyte stock soars after Symvess gains DOD electronic catalog listing

July 8, 2025 | in.investing.com

Humacyte Shares Climb on Symvess ECAT Listing

July 8, 2025 | marketwatch.com

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

July 8, 2025 | globenewswire.com

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

July 7, 2025 | msn.com

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Buy" from Analysts

July 7, 2025 | marketbeat.com

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

June 30, 2025 | zacks.com

Humacyte (NASDAQ:HUMA) Stock Rating Upgraded by Wall Street Zen

June 27, 2025 | marketbeat.com

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

June 26, 2025 | msn.com

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

June 18, 2025 | msn.com

Humacyte: Revenue Ramp From Symvess Incoming

June 11, 2025 | seekingalpha.com

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

June 9, 2025 | theglobeandmail.com

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

June 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, BNTC, HUMA, and ATXS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$5.97 -0.27 (-4.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.96 -0.01 (-0.17%)

As of 07/18/2025 04:04 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.06 +0.02 (+0.14%)

As of 07/18/2025 07:22 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Cellectis NASDAQ:CLLS

$1.82 -0.11 (-5.70%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.85 +0.03 (+1.65%)

As of 07/18/2025 07:46 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Humacyte NASDAQ:HUMA

$2.33 -0.09 (-3.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.39 +0.06 (+2.58%)

As of 07/18/2025 07:57 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time